Purespring Therapeutics, a London, UK-based gene therapy company focused on enhancing the treatment of kidney diseases, raised $105M in Series B funding.
The round was led by Sofinnova Partners, in collaboration with a syndicate including Gilde Healthcare, Forbion, British Patient Capital and founding investor Syncona Limited.
The company intends to use the funds to support its pipeline including the initiation of a Phase I/II clinical trial for IgAN, a common, chronic kidney disease primarily affecting young adults. Proceeds will be used to support the initiation of a Phase I/II clinical trial for IgAN, a common, chronic kidney disease primarily affecting young adults.
Led by CEO Julian Hanak, Purespring treats kidney disease models by directly targeting the podocyte, a specialised cell implicated in approximately 60% of renal diseases, through its proprietary adeno-associated viral (AAV) gene therapy platform. It currently has a pipeline of programmes in development. This includes its lead programme PS-002, in development for IgA Nephropathy (IgAN), and other complement mediated kidney diseases, a programme targeting nephrotic syndrome, and an undisclosed glomerular kidney disease programme.
Purespring will present its IgAN data publicly for the first time at the American Society of Nephrology (ASN) Kidney Week congress on October 26 in San Diego (abstract #SA-OR63).
FinSMEs
09/10/2024